Clinical Implications of VEGF, TGF-β1, and IL-1β in Patients with Advanced Non-small Cell Lung Cancer

Overview

Journal Cancer Res Treat

Specialty Oncology

Date 2014 Jan 24

PMID 24454005

Citations 28

Authors

Ji-Won Kim

Youngil Koh

Dong-Wan Kim

Yong-Oon Ahn

Tae Min Kim

Sae-Won Han

Do-Youn Oh

Se-Hoon Lee

Seock-Ah Im

Tae-You Kim

Dae Seog Heo

Yung-Jue Bang

Affiliations

Soon will be listed here.

Abstract

Purpose: Vascular endothelial growth factor (VEGF)-A, VEGF165b, interleukin (IL)-1β, and transforming growth factor (TGF)-β1 are known to influence tumor angiogenesis. Clinical implications of these cytokines need to be elucidated.

Materials And Methods: Using clinical data and baseline serum samples of 140 consecutive patients with advanced non-small cell lung cancer who received platinum-based combination chemotherapy, we investigated the association among serum cytokine levels, treatment outcomes, as well as leukocyte and platelet counts.

Results: The median age of patients was 64 years (range, 26 to 86 years). The male to female ratio was 104:36. High TGF-β1 and IL-1β levels were associated with shorter progression-free survival, and high VEGF-A and IL-1β levels were associated with shorter overall survival in the univariate analysis. VEGF165b was not related to the treatment outcomes. Leukocytosis and thrombocytosis were associated with shorter overall survival. The multivariate analysis demonstrated that VEGF-A, IL-1β, and leukocytosis were significant prognostic factors (p=0.0497, p=0.047, and p<0.001, respectively). Leukocytosis was not associated with recent pneumonia (p=0.937) and correlated with VEGF-A (p<0.001) and TGF-β1 (p=0.020) levels.

Conclusion: Serum VEGF-A, TGF-1β, and IL-1β levels, in addition to leukocyte and platelet counts, are shown to be associated with clinical outcomes. Leukocyte and platelet counts are correlated with serum VEGF-A and TGF-β1 levels.

Citing Articles

IL-1β in Neoplastic Disease and the Role of Its Tumor-Derived Form in the Progression and Treatment of Metastatic Prostate Cancer.

Oyende Y, Taus L, Fatatis A Cancers (Basel). 2025; 17(2).

PMID: 39858071 PMC: 11763358. DOI: 10.3390/cancers17020290.

Clinical assessment of TGFB1 and HP Relative Gene Expression in the Peripheral Blood of Prostate Cancer Patients.

Yahya M, Abdel Hameed F, Radwan N, Abdelgawad I, Soliman A Asian Pac J Cancer Prev. 2024; 25(2):709-717.

PMID: 38415559 PMC: 11077105. DOI: 10.31557/APJCP.2024.25.2.709.

IL-1β is involved in docetaxel chemoresistance by regulating the formation of polyploid giant cancer cells in non-small cell lung cancer.

Zhao S, Xing S, Wang L, Ouyang M, Liu S, Sun L Sci Rep. 2023; 13(1):12763.

PMID: 37550397 PMC: 10406903. DOI: 10.1038/s41598-023-39880-2.

IL-1β enhances cell viability and decreases 5-FU sensitivity in novel colon cancer cell lines derived from African American patients.

Spagnardi M, Paredes J, Zabaleta J, Garai J, Reyes T, Martello L Front Oncol. 2022; 12:1010380.

PMID: 36531053 PMC: 9754664. DOI: 10.3389/fonc.2022.1010380.

B Cell Receptor Signaling Pathway Mutation as Prognosis Predictor of Immune Checkpoint Inhibitors in Lung Adenocarcinoma by Bioinformatic Analysis.

Lin A, Fang J, Cheng Q, Liu Z, Luo P, Zhang J J Inflamm Res. 2022; 15:5541-5555.

PMID: 36176353 PMC: 9514294. DOI: 10.2147/JIR.S379016.

References

Lee J, Hong Y, Han C, Hwang D, Hong S . Clinical usefulness of serum and plasma vascular endothelial growth factor in cancer patients: which is the optimal specimen?. Int J Oncol. 2000; 17(1):149-52. View

Pertovaara L, Kaipainen A, Mustonen T, Orpana A, Ferrara N, Saksela O . Vascular endothelial growth factor is induced in response to transforming growth factor-beta in fibroblastic and epithelial cells. J Biol Chem. 1994; 269(9):6271-4. View

Letterio J, Roberts A . Regulation of immune responses by TGF-beta. Annu Rev Immunol. 1998; 16:137-61. DOI: 10.1146/annurev.immunol.16.1.137. View

Hasegawa Y, Takanashi S, Kanehira Y, Tsushima T, Imai T, Okumura K . Transforming growth factor-beta1 level correlates with angiogenesis, tumor progression, and prognosis in patients with nonsmall cell lung carcinoma. Cancer. 2001; 91(5):964-71. View

Woolard J, Wang W, Bevan H, Qiu Y, Morbidelli L, Pritchard-Jones R . VEGF165b, an inhibitory vascular endothelial growth factor splice variant: mechanism of action, in vivo effect on angiogenesis and endogenous protein expression. Cancer Res. 2004; 64(21):7822-35. DOI: 10.1158/0008-5472.CAN-04-0934. View

Therasse P, Arbuck S, Eisenhauer E, Wanders J, Kaplan R, Rubinstein L . New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000; 92(3):205-16. DOI: 10.1093/jnci/92.3.205. View

Assoian R, Komoriya A, Meyers C, Miller D, Sporn M . Transforming growth factor-beta in human platelets. Identification of a major storage site, purification, and characterization. J Biol Chem. 1983; 258(11):7155-60. View

Shchors K, Evan G . Tumor angiogenesis: cause or consequence of cancer?. Cancer Res. 2007; 67(15):7059-61. DOI: 10.1158/0008-5472.CAN-07-2053. View

Dinarello C . The interleukin-1 family: 10 years of discovery. FASEB J. 1994; 8(15):1314-25. View

10.

Choi J, Kim H, Lim H, Nam D, Kim H, Yi J . Vascular endothelial growth factor in the serum of patients with non-small cell lung cancer: correlation with platelet and leukocyte counts. Lung Cancer. 2001; 33(2-3):171-9. DOI: 10.1016/s0169-5002(01)00200-8. View

11.

Ivanovic V, Todorovic-Rakovic N, Demajo M, Neskovic-Konstantinovic Z, Subota V, Ivanisevic-Milovanovic O . Elevated plasma levels of transforming growth factor-beta 1 (TGF-beta 1) in patients with advanced breast cancer: association with disease progression. Eur J Cancer. 2003; 39(4):454-61. DOI: 10.1016/s0959-8049(02)00502-6. View

12.

Bremnes R, Camps C, Sirera R . Angiogenesis in non-small cell lung cancer: the prognostic impact of neoangiogenesis and the cytokines VEGF and bFGF in tumours and blood. Lung Cancer. 2005; 51(2):143-58. DOI: 10.1016/j.lungcan.2005.09.005. View

13.

Zeisler H, Tempfer C, Joura E, Sliutz G, Koelbl H, Wagner O . Serum interleukin 1 in ovarian cancer patients. Eur J Cancer. 1998; 34(6):931-3. DOI: 10.1016/s0959-8049(97)10107-1. View

14.

Foekens J, Peters H, Grebenchtchikov N, Look M, Meijer-van Gelder M, Geurts-Moespot A . High tumor levels of vascular endothelial growth factor predict poor response to systemic therapy in advanced breast cancer. Cancer Res. 2001; 61(14):5407-14. View

15.

Chod J, Zavadova E, Halaska M, Strnad P, Fucikova T, Rob L . Preoperative transforming growth factor-beta 1 (TGF-beta 1) plasma levels in operable breast cancer patients. Eur J Gynaecol Oncol. 2009; 29(6):613-6. View

16.

Ladomery M, Harper S, Bates D . Alternative splicing in angiogenesis: the vascular endothelial growth factor paradigm. Cancer Lett. 2006; 249(2):133-42. DOI: 10.1016/j.canlet.2006.08.015. View

17.

Beasley M, Brambilla E, Travis W . The 2004 World Health Organization classification of lung tumors. Semin Roentgenol. 2005; 40(2):90-7. DOI: 10.1053/j.ro.2005.01.001. View

18.

Mohle R, Green D, Moore M, Nachman R, Rafii S . Constitutive production and thrombin-induced release of vascular endothelial growth factor by human megakaryocytes and platelets. Proc Natl Acad Sci U S A. 1997; 94(2):663-8. PMC: 19570. DOI: 10.1073/pnas.94.2.663. View

19.

Poon R, Fan S, Wong J . Clinical implications of circulating angiogenic factors in cancer patients. J Clin Oncol. 2001; 19(4):1207-25. DOI: 10.1200/JCO.2001.19.4.1207. View

20.

Shariat S, Kattan M, Traxel E, Andrews B, Zhu K, Wheeler T . Association of pre- and postoperative plasma levels of transforming growth factor beta(1) and interleukin 6 and its soluble receptor with prostate cancer progression. Clin Cancer Res. 2004; 10(6):1992-9. DOI: 10.1158/1078-0432.ccr-0768-03. View